[go: up one dir, main page]

AR121803A1 - COMPOSITIONS AND METHODS FOR DELIVERY TO THE BLOOD-BRAIN BARRIER - Google Patents

COMPOSITIONS AND METHODS FOR DELIVERY TO THE BLOOD-BRAIN BARRIER

Info

Publication number
AR121803A1
AR121803A1 ARP210100938A ARP210100938A AR121803A1 AR 121803 A1 AR121803 A1 AR 121803A1 AR P210100938 A ARP210100938 A AR P210100938A AR P210100938 A ARP210100938 A AR P210100938A AR 121803 A1 AR121803 A1 AR 121803A1
Authority
AR
Argentina
Prior art keywords
blood
antigen
brain barrier
delivery
compositions
Prior art date
Application number
ARP210100938A
Other languages
Spanish (es)
Inventor
Suzanne Edavettal
Sanjaya Singh
Derrick Domingo
Deepti Wilkinson
Pilar Cejudo-Martin
Pharavee Jaisprasart
Brian Geist
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of AR121803A1 publication Critical patent/AR121803A1/en

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen anticuerpos monoclonales anti-TfR y fragmentos de unión al antígeno de estos para suministrar un agente al cerebro de un sujeto que lo necesita. Además, se describen conjugados y construcciones de fusión que contienen el anticuerpo anti-TfR o fragmento de unión al antígeno de este acoplado a un agente terapéutico o de diagnóstico, tal como un segundo anticuerpo y fragmento de unión al antígeno de este, para tratar o detectar un trastorno neurológico y/o suministrar un agente terapéutico o de diagnóstico a través de la barrera hematoencefálica. También se describen ácidos nucleicos que codifican los anticuerpos, conjugados y constructos de fusión y células huésped recombinantes relacionadas.Anti-TfR monoclonal antibodies and antigen-binding fragments thereof for delivering an agent to the brain of a subject in need thereof are disclosed. In addition, conjugates and fusion constructs containing the anti-TfR antibody or antigen-binding fragment thereof coupled to a therapeutic or diagnostic agent, such as a second antibody and antigen-binding fragment thereof, for treating or detect a neurological disorder and/or deliver a diagnostic or therapeutic agent across the blood-brain barrier. Nucleic acids encoding the antibodies, conjugates and fusion constructs, and related recombinant host cells are also disclosed.

ARP210100938A 2020-04-08 2021-04-08 COMPOSITIONS AND METHODS FOR DELIVERY TO THE BLOOD-BRAIN BARRIER AR121803A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063006998P 2020-04-08 2020-04-08

Publications (1)

Publication Number Publication Date
AR121803A1 true AR121803A1 (en) 2022-07-13

Family

ID=83218600

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100938A AR121803A1 (en) 2020-04-08 2021-04-08 COMPOSITIONS AND METHODS FOR DELIVERY TO THE BLOOD-BRAIN BARRIER

Country Status (1)

Country Link
AR (1) AR121803A1 (en)

Similar Documents

Publication Publication Date Title
AR127520A2 (en) COMPOSITIONS AND METHODS FOR DELIVERY TO THE BLOOD-BRAIN BARRIER
AR127518A2 (en) ANTI-CD98 ANTIBODIES AND USES OF THESE
US9546206B2 (en) High affinity PD-1 agents and methods of use
BR112015010046A2 (en) ANTIGEN-BINDING PROTEINS OR AN ANTIGEN-BINDING FRAGMENT THEREOF AND THEIR METHOD OF PRODUCTION, VECTOR, TRANSGENIC MICROORGANISM HOST CELL, IMMUNOCONJUGATE AND THEIR USE, PHARMACEUTICAL COMPOSITION AND MURINE HYBRIDOMA
Muthumani et al. Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody
CO6351751A2 (en) HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
RU2018139811A (en) MULTI-SPECIFIC ANTI-BINDING CONSTRUCTIONS TARGETING IMMUNOTHERAPEUTIC MEANS
MX2023003039A (en) AGENTS AND METHODS FOR DELIVERY DIRECTED TO CELLS.
MX2024010983A (en) Dna monoclonal antibodies targeting checkpoint molecules.
Lysén et al. Dendritic cell targeted Ccl3-and Xcl1-fusion DNA vaccines differ in induced immune responses and optimal delivery site
WO2017193101A1 (en) Dna antibody constructs for use against pseudomonas aeruginosa
BR112021001237A2 (en) humanized antibodies against psma
Ghaemi et al. Recombinant COVID-19 vaccine based on recombinant RBD/Nucleoprotein and saponin adjuvant induces long-lasting neutralizing antibodies and cellular immunity
ES3036457T3 (en) A cd33-, cd16- and cd123-specific single chain triplebody
NZ750948A (en) Anti-gp73 antibodies and immunoconjugates
ES3032333T3 (en) The in vivo use of chondroitinase and/or hyaluronidase to enhance delivery of an agent
Zhou et al. DEC205-DC targeted DNA vaccines to CX3CR1 and CCL2 are potent and limit macrophage migration
Dashti et al. Preclinical assessment of a recombinant RBD-Fc fusion protein as SARS-CoV-2 candidate vaccine
AR121803A1 (en) COMPOSITIONS AND METHODS FOR DELIVERY TO THE BLOOD-BRAIN BARRIER
AR121802A1 (en) ANTI-CD98 ANTIBODIES AND THEIR USES
BR112023025810A2 (en) AGENTS AND METHODS FOR ACTIVATING AND TARGETING IMMUNE EFFECTOR CELLS
Swart et al. Enhancing breadth and durability of humoral immune responses in non-human primates with an adjuvanted group 1 influenza hemagglutinin stem antigen
MX2024011081A (en) MULTISPECIFIC ANTIBODIES AND THEIR USES.
US11952410B2 (en) Mesothelin-targeted trail trimer
PT1694709E (en) Recombinant anti-cd64-eta` immunotoxins